

Global Dacryocystitis Market Size study, by Treatment (Surgery, Medication [Antibiotics]), by Indication (Chronic Dacryocystitis, Acute Dacryocystitis, Congenital Dacryocystitis), by End User (Institutional Sales, Retail Sales) and Regional Forecasts 2022-2032

<https://marketpublishers.com/r/G7B2AA6256D7EN.html>

Date: May 2025

Pages: 285

Price: US\$ 3,218.00 (Single User License)

ID: G7B2AA6256D7EN

Abstracts

Global Dacryocystitis Market is valued approximately at USD 40.6 billion in 2023 and is anticipated to grow with a steady compound annual growth rate of more than 5.20% over the forecast period 2024–2032. Dacryocystitis, a condition characterized by inflammation and infection of the lacrimal sac, has drawn increasing clinical and commercial attention due to the rising incidence of ocular infections and age-related nasolacrimal duct obstructions. This ophthalmic disorder can manifest acutely or chronically and demands a multifaceted therapeutic approach including both pharmacological interventions such as antibiotics and surgical procedures like dacryocystorhinostomy. With a global upsurge in ophthalmologic consultations and an aging population prone to eye-related ailments, the market for dacryocystitis therapeutics and interventions is witnessing accelerated expansion, backed by innovation and healthcare infrastructure enhancements.

The market's upward trajectory is being actively propelled by heightened awareness surrounding early diagnosis and treatment compliance, especially in pediatric and geriatric cohorts, where congenital and chronic forms are more prevalent. The World Health Organization and regional health ministries have increasingly emphasized accessible ophthalmic care, stimulating institutional investments in diagnostic imaging tools and surgical expertise. Moreover, the evolution of antibiotic resistance has driven pharmaceutical firms to explore novel antibiotic combinations and targeted drug delivery systems to overcome therapeutic gaps. These factors, coupled with increased adoption of minimally invasive procedures in tertiary care settings, have shifted the treatment

paradigm toward more precise and patient-centric modalities. However, cost-intensive surgeries and variability in access across low-income regions continue to be deterrents to uniform market penetration.

North America currently holds a significant share of the global dacryocystitis market, owing to its robust reimbursement frameworks, a high concentration of specialized ophthalmologists, and strong public awareness. The U.S., in particular, has seen notable advancements in ambulatory eye care technologies and outpatient dacryocystorhinostomy procedures. Europe follows closely, backed by a dense network of public healthcare providers and academic institutions involved in ophthalmology-focused R&D. Conversely, the Asia Pacific region is projected to witness the fastest CAGR over the forecast timeline, driven by population growth, increased healthcare access in urban clusters, and governmental focus on vision-related health issues. Nations like India, China, and Japan are leading the regional adoption with growing investments in primary and secondary ophthalmic care.

Latin America and the Middle East & Africa represent emerging opportunities for market stakeholders, despite challenges in infrastructure and awareness. Countries such as Brazil and South Africa have initiated collaborative programs with global health agencies to integrate basic ophthalmic diagnostics into community clinics. Furthermore, mobile healthcare units and digital screening platforms are being leveraged to improve early detection rates in rural and underserved geographies. The proliferation of retail and online pharmacies across these regions is also aiding the distribution of prescription antibiotics and post-surgical maintenance drugs, allowing for better continuity of care post-discharge.

Major market player included in this report are:

Novartis AG

Allergan Plc (AbbVie Inc.)

Pfizer Inc.

Bausch + Lomb Incorporated

Sun Pharmaceutical Industries Ltd.

Johnson & Johnson

Cipla Limited

F. Hoffmann-La Roche Ltd

Akorn Operating Company LLC

Teva Pharmaceutical Industries Ltd.

Alcon Inc.

Mylan N.V.

Valeant Pharmaceuticals International Inc.

Santen Pharmaceutical Co., Ltd.

Aurobindo Pharma Limited

The detailed segments and sub-segment of the market are explained below:

By Treatment

Surgery

Medication

Antibiotics

By Indication

Chronic Dacryocystitis

Acute Dacryocystitis

Congenital Dacryocystitis

By End User

Institutional Sales

Retail Sales

By Region:

North America

U.S.

Canada

Europe

UK

Germany

France

Spain

Italy

Rest of Europe

Asia Pacific

China

India

Japan

Australia

South Korea

Rest of Asia Pacific

Latin America

Brazil

Mexico

Rest of Latin America

Middle East & Africa

Saudi Arabia

South Africa

Rest of Middle East & Africa

Years considered for the study are as follows:

Historical year – 2022

Base year – 2023

Forecast period – 2024 to 2032

Key Takeaways:

Market Estimates & Forecast for 10 years from 2022 to 2032.

Annualized revenues and regional level analysis for each market segment.

Detailed analysis of geographical landscape with Country level analysis of major regions.

Competitive landscape with information on major players in the market.

Analysis of key business strategies and recommendations on future market approach.

Analysis of competitive structure of the market.

Demand side and supply side analysis of the market.

Contents

CHAPTER 1. GLOBAL DACRYOCYSTITIS MARKET EXECUTIVE SUMMARY

- 1.1. Global Dacryocystitis Market Size & Forecast (2022–2032)
- 1.2. Regional Summary
- 1.3. Segmental Summary
 - 1.3.1. By Treatment
 - 1.3.2. By Indication
 - 1.3.3. By End User
- 1.4. Key Trends
- 1.5. Recession Impact
- 1.6. Analyst Recommendation & Conclusion

CHAPTER 2. GLOBAL DACRYOCYSTITIS MARKET DEFINITION AND RESEARCH ASSUMPTIONS

- 2.1. Research Objective
- 2.2. Market Definition
- 2.3. Research Assumptions
 - 2.3.1. Inclusion & Exclusion
 - 2.3.2. Limitations
 - 2.3.3. Supply Side Analysis
 - 2.3.3.1. Availability
 - 2.3.3.2. Infrastructure
 - 2.3.3.3. Regulatory Environment
 - 2.3.3.4. Market Competition
 - 2.3.3.5. Economic Viability (Patient's Perspective)
 - 2.3.4. Demand Side Analysis
 - 2.3.4.1. Regulatory Frameworks
 - 2.3.4.2. Technological Advancements
 - 2.3.4.3. Health & Safety Considerations
 - 2.3.4.4. Patient Awareness & Adoption
- 2.4. Estimation Methodology
- 2.5. Years Considered for the Study
 - Historical year – 2022
 - Base year – 2023
 - Forecast period – 2024 to 2032
- 2.6. Currency Conversion Rates

CHAPTER 3. GLOBAL DACRYOCYSTITIS MARKET DYNAMICS

3.1. Market Drivers

- 3.1.1. Rise in Ocular Infections and Nasolacrimal Obstructions
- 3.1.2. Endorsement by WHO and Public Health Initiatives
- 3.1.3. Advances in Minimally Invasive Surgical Techniques

3.2. Market Challenges

- 3.2.1. Cost-intensive Surgical Procedures
- 3.2.2. Antibiotic Resistance and Treatment Failures
- 3.2.3. Inconsistent Access in Low-resource Regions

3.3. Market Opportunities

- 3.3.1. Development of Targeted Antibiotic Formulations
- 3.3.2. Expansion of Ambulatory and Outpatient Services
- 3.3.3. Digital Screening and Tele-ophthalmology Integration

CHAPTER 4. GLOBAL DACRYOCYSTITIS MARKET INDUSTRY ANALYSIS

4.1. Porter's 5 Force Model

- 4.1.1. Bargaining Power of Suppliers
- 4.1.2. Bargaining Power of Buyers
- 4.1.3. Threat of New Entrants
- 4.1.4. Threat of Substitutes
- 4.1.5. Competitive Rivalry
- 4.1.6. Futuristic Approach to Porter's 5 Force Model
- 4.1.7. Porter's 5 Force Impact Analysis

4.2. PESTEL Analysis

- 4.2.1. Political
- 4.2.2. Economic
- 4.2.3. Social
- 4.2.4. Technological
- 4.2.5. Environmental
- 4.2.6. Legal

4.3. Top Investment Opportunities

4.4. Top Winning Strategies

4.5. Disruptive Trends

4.6. Industry Expert Perspective

4.7. Analyst Recommendation & Conclusion

CHAPTER 5. GLOBAL DACRYOCYSTITIS MARKET SIZE & FORECASTS BY TREATMENT 2022–2032

5.1. Segment Dashboard

5.2. Global Dacryocystitis Market: Treatment Revenue Trend Analysis, 2022 & 2032 (USD Billion)

5.2.1. Surgery

5.2.2. Medication (Antibiotics)

CHAPTER 6. GLOBAL DACRYOCYSTITIS MARKET SIZE & FORECASTS BY INDICATION 2022–2032

6.1. Segment Dashboard

6.2. Global Dacryocystitis Market: Indication Revenue Trend Analysis, 2022 & 2032 (USD Billion)

6.2.1. Chronic Dacryocystitis

6.2.2. Acute Dacryocystitis

6.2.3. Congenital Dacryocystitis

CHAPTER 7. GLOBAL DACRYOCYSTITIS MARKET SIZE & FORECASTS BY END USER 2022–2032

7.1. Segment Dashboard

7.2. Global Dacryocystitis Market: End User Revenue Trend Analysis, 2022 & 2032 (USD Billion)

7.2.1. Institutional Sales

7.2.2. Retail Sales

CHAPTER 8. GLOBAL DACRYOCYSTITIS MARKET SIZE & FORECASTS BY REGION 2022–2032

8.1. North America Dacryocystitis Market

8.1.1. U.S. Dacryocystitis Market

8.1.1.1. Treatment breakdown size & forecasts, 2022–2032

8.1.1.2. End User breakdown size & forecasts, 2022–2032

8.1.2. Canada Dacryocystitis Market

8.2. Europe Dacryocystitis Market

8.2.1. U.K. Dacryocystitis Market

8.2.2. Germany Dacryocystitis Market

- 8.2.3. France Dacryocystitis Market
- 8.2.4. Spain Dacryocystitis Market
- 8.2.5. Italy Dacryocystitis Market
- 8.2.6. Rest of Europe Dacryocystitis Market
- 8.3. Asia-Pacific Dacryocystitis Market
 - 8.3.1. China Dacryocystitis Market
 - 8.3.2. India Dacryocystitis Market
 - 8.3.3. Japan Dacryocystitis Market
 - 8.3.4. Australia Dacryocystitis Market
 - 8.3.5. South Korea Dacryocystitis Market
 - 8.3.6. Rest of Asia Pacific Dacryocystitis Market
- 8.4. Latin America Dacryocystitis Market
 - 8.4.1. Brazil Dacryocystitis Market
 - 8.4.2. Mexico Dacryocystitis Market
 - 8.4.3. Rest of Latin America Dacryocystitis Market
- 8.5. Middle East & Africa Dacryocystitis Market
 - 8.5.1. Saudi Arabia Dacryocystitis Market
 - 8.5.2. South Africa Dacryocystitis Market
 - 8.5.3. Rest of Middle East & Africa Dacryocystitis Market

CHAPTER 9. COMPETITIVE INTELLIGENCE

- 9.1. Key Company SWOT Analysis
 - 9.1.1. Novartis AG
 - 9.1.2. Allergan Plc (AbbVie Inc.)
 - 9.1.3. Pfizer Inc.
- 9.2. Top Market Strategies
- 9.3. Company Profiles
 - 9.3.1. Novartis AG
 - 9.3.1.1. Key Information
 - 9.3.1.2. Overview
 - 9.3.1.3. Financial (Subject to Data Availability)
 - 9.3.1.4. Product Summary
 - 9.3.1.5. Market Strategies
 - 9.3.2. Allergan Plc (AbbVie Inc.)
 - 9.3.3. Pfizer Inc.
 - 9.3.4. Bausch + Lomb Incorporated
 - 9.3.5. Sun Pharmaceutical Industries Ltd.
 - 9.3.6. Johnson & Johnson

9.3.7. Cipla Limited

9.3.8. F. Hoffmann-La Roche Ltd

CHAPTER 10. RESEARCH PROCESS

10.1. Research Process

10.1.1. Data Mining

10.1.2. Analysis

10.1.3. Market Estimation

10.1.4. Validation

10.1.5. Publishing

10.2. Research Attributes

I would like to order

Product name: Global Dacryocystitis Market Size study, by Treatment (Surgery, Medication [Antibiotics]), by Indication (Chronic Dacryocystitis, Acute Dacryocystitis, Congenital Dacryocystitis), by End User (Institutional Sales, Retail Sales) and Regional Forecasts 2022-2032

Product link: <https://marketpublishers.com/r/G7B2AA6256D7EN.html>

Price: US\$ 3,218.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G7B2AA6256D7EN.html>